Clinical data | |
---|---|
Other names | ENS-103 |
Routes of administration | By mouth |
Drug class | NMDA receptor antagonist |
Identifiers | |
CAS Number |
EVT-103, also known as ENS-103, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder. [1] It acts as an NMDA receptor subunit 2B (NR2B) antagonist. [1] As of November 2017, no recent reports of development for major depressive disorder have been identified. [1] The drug was developed as a follow-up compound to EVT-101. [2] The chemical structure of EVT-103 has not been released. [2]